Although the incidence of hepatic clinical adverse activities with vildagliptin did not vary appreciably from placebo, individuals with liver disorder were not included in trials.Overall body fat significantly impacts the pharmacokinetics of liraglutide depending on benefits of population pharmacokinetic analyses carried out in individuals with ent